Vaccination with the chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria

Infection and Immunity

Volumn 73, Issue 12, 2005, Pages 8153-8160

  Pal, Sukumar ^a   Peterson, Ellena M ^a   De La Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALHYDROGEL 85; ALUMINUM HYDROXIDE; BACTERIAL VACCINE; CPG OLIGODEOXYNUCLEOTIDE 1826; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; OLIGODEOXYNUCLEOTIDE; OUTER MEMBRANE PROTEIN; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMORAL IMMUNITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VACCINATION; VAGINA SMEAR;

ANIMALS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; INFERTILITY, FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MICE; PORINS; PREGNANCY; VAGINA;

EID: 28444470161     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.12.8153-8160.2005     Document Type: Article

References (58)

1. Abel, K., T. Rourke, D. Lu, K. Bost, M. B. McChesney, and C. J. Miller. 2004. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239. J. Infect. Dis. 190:1697-1705.
2. Baher, W., Y. X. Zhang, T. Joseph, H. Su, F. E. Nano, K. D. E. Everett, and H. D. Caldwell. 1988. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc. Natl. Acad. Sci. USA 85:4000-4004.
3. Batteiger, B. E., R. G. Rank, P. M. Bavoil, and L. S. Soderberg. 1993. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J. Gen. Microbiol. 139:2965-2972.
4. Berry, L. J., D. K. Hickey, K. A. Skelding, S. Bao, A. M. Rendina, P. M. Hansbro, C. M. Gockel, and K. W. Beagley. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72:1019-1028.
5. Blake, M. S., and E. C. Gotschlich. 1984. Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae. J. Exp. Med. 159:452-462.
6. Caldwell, H. D., J. Kromhout, and J. Schachter. 1981. Purification and characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176.
7. Cheng, X., S. Pal, L. M. de la Maza, and E. M. Peterson. 1992. Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E. Infect. Immun. 60:3428-3432.
8. Davis, H. L., C. L. Cooper, M. L. Morris, S. M. Elfer, D. W. Cameron, and J. Heathcote. 2000. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: preliminary results of phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Research, abstr. S25.
9. de la Maza, L. M., S. Pal, A. Khamesipour, and E. M. Peterson. 1994. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect. Immun. 62:2094-2097.
10. de la Maza, L. M., and E. M. Peterson. 2002. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Investig. Drugs 3:980-986.
11. de la Maza, M. A., and L. M. de la Maza. 1995. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13:119-127.
12. Engers, H., M. P. Kieny, P. Malhotra, and J. R. Pink. 2003. Third meeting on novel adjuvants currently in or close to clinical testing. World Health Organization-Organisation Mondiale de la Sante, Fondation Merieux, Annecy, France, 7-9 January 2002. Vaccine 21:3503-3524.
13. Gillgrass, A. E., A. A. Ashkar, K. L. Rosenthal, and C. Kaushic. 2003. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 77:9845-9851.
14. Grayston, J. T., and S.-P. Wang. 1975. New knowledge of chlamydiae and the diseases they cause. J. Infect. Dis. 132:87-105.
15. Grayston, J. T., and S. P. Wang. 1978. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex. Transm. Dis. 5:73-77.
16. Hatch, T. P. 1996. Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? J. Bacteriol. 178:1-5.
17. 19) formulated in oil-based Montanides. Vaccine 21:2923-2932.
18. Igietseme, J. U., C. M. Black, and H. D. Caldwell. 2002. Chlamydia vaccines: strategies and status. BioDrugs 16:19-35.
19. Kaushic, C., A. D. Murdin, B. J. Underdown, and C. R. Wira. 1998. Chlamydia trachomatis infection in the female reproductive tract of the rat: influence of progesterone on infectivity and immune response. Infect. Immun. 66:893-898.
20. Kaushic, C., F. Zhou, B. J. Underdown, and C. R. Wira. 2000. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect. Immun. 68:4207-4216.
21. Kelly, K. A., J. C. Walker, S. H. Jameel, H. L. Gray, and R. G. Rank. 2000. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia infection. Infect. Immun. 68:1519-1528.
22. LaMontagne, D. S., D. N. Fine, and J. M. Marrazzo. 2003. Chlamydia trachomatis infection in asymptomatic men. Am. J. Prev. Med. 24:36-42.
23. Lindblad, E. B. 2004. Aluminium adjuvants-in retrospect and prospect. Vaccine 22:3658-3668.
24. Miller, W. C., C. A. Ford, M. Morris, M. S. Handcock, J. L. Schmitz, M. M. Hubbs, M. S. Cohen, K. M. Harris, and J. R. Udry. 2004. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 291:2229-2236.
25. Millman, K., C. M. Black, R. E. Johnson, W. E. Stamm, R. B. Jones, E. W. Hook, D. H. Martin, G. Bolan, S. Tavare, and D. Dean. 2004. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J. Bacteriol. 186:2457-2465.
26. Morrison, R. P., R. J. Belland, K. Lyng, and H. D. Caldwell. 1989. Chlamydial disease pathogenesis. The 57-kDa chlamydial hypersensitivity antigen is a stress response protein. J. Exp. Med. 170:113-122.
27. Morrison, R. P., and H. D. Caldwell. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70:2741-2751.
28. + T cells. Infect. Immun. 69:2643-2649.
29. + T cells. Infect. Immun. 68:6979-6987.
30. Nigg, C. 1942. An unidentified virus which produces pneumonia and systemic infection in mice. Science 99:49-50.
31. Pal, S., K. M. Barnhart, Q. Wei, A. M. Abai, E. M. Peterson, and L. M. de la Maza. 1999. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-465.
32. Pal, S., H. L. Davis, E. M. Peterson, and L. M. de la Maza. 2002. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect. Immun. 70:4812-4817.
33. Pal, S., T. J. Fielder, E. M. Peterson, and L. M. de la Maza. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62:3354-3362.
34. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 1997. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65:3361-3369.
35. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69:6240-6247.
36. Peterson, E. M., G. Zhong, E. Carlson, and L. M. de la Maza. 1988. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect. Immun. 56:885-891.
37. Piccinni, M. P., M. G. Giudizi, R. Biagiotti, L. Beloni, L. Giannarini, S. Sampognaro, P. Parronchi, R. Manetti, F. Annunziato, C. Livi, S. Romagnani, and E. Maggi. 1995. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol. 155:128-133.
38. Ramsey, K. H., T. W. Cotter, R. D. Salyer, G. S. Miranpuri, M. A. Yanez, C. E. Poulsen, J. L. DeWolfe, and G. I. Byrne. 1999. Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect. Immun. 67:3019-3025.
39. Rank, R. G. 1999. Models of immunity, p. 239-296. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis and immunity. American Society for Microbiology, Washington, D.C.
40. Rodriguez-Marañon, M. J., R. M. Bush, E. M. Peterson, T. Schirmer, and L. M. de la Maza. 2002. Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci. 11:1854-1861.
41. Schachter, J. 1999. Infection and disease epidemiology, p. 139-170. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis and immunity. American Society for Microbiology, Washington, D.C.
42. Schachter, J., and C. Dawson. 1978. Human chlamydial infections. PSG Publishing Company, Inc., Littleton, Mass.
43. Schagger, H., and G. von Jagow. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368-379.
44. Stamm, W. K. 1999. Chlamydia trachomatis infections of the adult, p. 407-422. In K. K. Holmes et al. (ed.), Sexually transmitted diseases. McGraw-Hill, New York, N.Y.
45. Stephens, R. S., R. Sanchez-Pescador. E. A. Wagar, C. Inouye, and M. S. Urdea. 1987. Diversity of Chlamydia trachomatis major outer membrane protein genes. J. Bacteriol. 169:3879-3885.
46. Stephens, R. S., K. A. Wagar, and G. K. Schoolnick. 1988. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med. 167: 817-831.
47. Stratton, K. R., J. S. Durch, and R. S. Lawrence (ed.). 2000. Vaccines for the 21st century: a tool for decision making. National Academy Press, Washington, D.C.
48. Su, H., and H. D. Caldwell. 1992. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein. J. Exp. Med. 75:227-235.
49. Su, H., R. Messer, W. Whitmire, E. Fisher, J. C. Portis, and H. B. Caldwell. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J. Exp. Med. 188:809-818.
50. Taylor, H. R., J. Whittum-Hudson, J. Schachter, H. D. Caldwell, and R. A. Prendergast. 1988. Oral immunization with chlamydial major outer membrane protein (MOMP). Investig. Ophthalmol. Vis. Sci. 29:1847-1853.
51. Tuffrey, M., F. Alexander, W. Conlan, C. Woods, and M. Ward. 1992. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J. Gen. Microbiol. 148:1707-1715.
52. Wang, S.-P., and J. T. Graysion. 1963. Classification of trachoma virus strains by protection of mice from toxic death. J. Immunol. 90:849-856.
53. Wang, S.-P., and J. T. Grayston. 1984. Micro-immunofluorescence serology of Chlamydia trachomatis, p. 87-118. In L. M. de la Maza and E. M. Peterson (ed.), Medical virology III. Elsevier Science Publishing Co., Inc., New York, N.Y.
54. Weeratna, R. D., M. J. McCluskie, Y. Xu, and H. L. Davis. 2000. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18:1755-1762.
55. Westrom, L., R. Joesoef, G. Reynolds, A. Hagdu, and S. E. Thompson. 1992. Pelvic inflammatory disease and fertility, a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopy. Sex. Transm. Dis. 19:185-192.
56. Yen, T.-T., S. Pal, and L. M. de la Maza. 2005. Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry 44:6250-6256.
57. Zhang, D. J., J. Berry, C. Shen, G. McClarty, and R. C. Brunham. 1997. DNA vaccination with the major outer-membrane protein gene induces immunity to Chlamydia trachomatis (mouse pneumonitis infection). J. Infect. Dis. 176:1035-1040.
58. Zhang, D.-J., X. Yang, C. Shen, H. Lu, A. Murdin, and R. C. Brunham. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 68:3074-3078.